TW202515576A - 治療眼表痛之方法 - Google Patents

治療眼表痛之方法 Download PDF

Info

Publication number
TW202515576A
TW202515576A TW113123791A TW113123791A TW202515576A TW 202515576 A TW202515576 A TW 202515576A TW 113123791 A TW113123791 A TW 113123791A TW 113123791 A TW113123791 A TW 113123791A TW 202515576 A TW202515576 A TW 202515576A
Authority
TW
Taiwan
Prior art keywords
pain
compound
corneal
formula
administration
Prior art date
Application number
TW113123791A
Other languages
English (en)
Chinese (zh)
Inventor
昆塔斯 麥德利
茂木宗人
帕瑪 米凱拉 蒙太奇
卡利歐彼 史塔西
Original Assignee
愛爾蘭商博士倫愛爾蘭有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商博士倫愛爾蘭有限公司 filed Critical 愛爾蘭商博士倫愛爾蘭有限公司
Publication of TW202515576A publication Critical patent/TW202515576A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW113123791A 2019-02-15 2020-02-13 治療眼表痛之方法 TW202515576A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806682P 2019-02-15 2019-02-15
US62/806,682 2019-02-15

Publications (1)

Publication Number Publication Date
TW202515576A true TW202515576A (zh) 2025-04-16

Family

ID=69740423

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113123791A TW202515576A (zh) 2019-02-15 2020-02-13 治療眼表痛之方法
TW109104537A TWI878266B (zh) 2019-02-15 2020-02-13 治療眼表痛之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109104537A TWI878266B (zh) 2019-02-15 2020-02-13 治療眼表痛之方法

Country Status (17)

Country Link
US (4) US20200261456A1 (https=)
EP (1) EP3923909A1 (https=)
JP (2) JP7571037B2 (https=)
KR (1) KR20210129677A (https=)
CN (1) CN113453686B (https=)
AU (2) AU2020222348B2 (https=)
BR (1) BR112021015998A2 (https=)
CA (1) CA3130038A1 (https=)
CL (1) CL2021002152A1 (https=)
IL (1) IL284629A (https=)
JO (1) JOP20210217A1 (https=)
MX (2) MX2021009702A (https=)
PH (1) PH12021551968A1 (https=)
SG (1) SG11202107260VA (https=)
TW (2) TW202515576A (https=)
WO (1) WO2020165838A1 (https=)
ZA (1) ZA202104593B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
WO2022029656A1 (en) * 2020-08-06 2022-02-10 Novartis Ag Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
CN119184616A (zh) * 2024-09-03 2024-12-27 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) 一种疼痛等级的测评方法及其评估系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US7893260B2 (en) 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
BRPI0620264A2 (pt) 2005-12-22 2011-11-08 Prolexys Pharmaceuticals Inc quinazolonas aril-substituìdas e sua utilização
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
AR067631A1 (es) 2007-07-18 2009-10-21 Novartis Ag Combinaciones sinergicas de antagonistas de vr-1 e inhibidores de cox-2 , composicion farmaceutica y uso
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
CA2707441A1 (en) 2008-01-09 2009-07-16 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
CN109790116B (zh) 2016-09-20 2022-10-28 葛兰素史密斯克莱知识产权(第2 号)有限公司 Trpv4拮抗剂
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產(第二)有限公司 Trpv4拮抗劑
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
JP2022520410A (ja) * 2019-02-15 2022-03-30 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの結晶形態及びその製剤

Also Published As

Publication number Publication date
AU2020222348A1 (en) 2021-08-05
BR112021015998A2 (pt) 2021-10-05
ZA202104593B (en) 2025-03-26
JP2022520832A (ja) 2022-04-01
JP2025004186A (ja) 2025-01-14
IL284629A (en) 2021-08-31
US20210275529A1 (en) 2021-09-09
CN113453686A (zh) 2021-09-28
PH12021551968A1 (en) 2022-05-23
JP7571037B2 (ja) 2024-10-22
TW202045179A (zh) 2020-12-16
WO2020165838A9 (en) 2021-03-18
KR20210129677A (ko) 2021-10-28
AU2023203716B2 (en) 2025-03-20
US20220193078A1 (en) 2022-06-23
MX2021009702A (es) 2021-09-14
SG11202107260VA (en) 2021-08-30
US20240342174A1 (en) 2024-10-17
TWI878266B (zh) 2025-04-01
MX2025000353A (es) 2025-02-10
EP3923909A1 (en) 2021-12-22
CN113453686B (zh) 2025-04-15
US11234982B2 (en) 2022-02-01
JOP20210217A1 (ar) 2023-01-30
WO2020165838A1 (en) 2020-08-20
AU2020222348B2 (en) 2023-03-16
CL2021002152A1 (es) 2022-04-18
US20200261456A1 (en) 2020-08-20
CA3130038A1 (en) 2020-08-20
AU2023203716A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
CN111568906B (zh) 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的配制品
AU2023203716B2 (en) Methods for treating ocular surface pain
RU2850452C2 (ru) Способы лечения боли на поверхности глаза
KR20260057219A (ko) 4-(7-히드록시-2-이소프로필-4-옥소-4h-퀴나졸린-3-일)-벤조니트릴의제형